Spravato

A fast-acting, FDA-approved nasal spray for treatment-resistant depression, administered under medical supervision. A typical course of Spravato requires a minimum of 8 sessions.

CONNECT WITH

Add your insurance to activate your benefits,
and browse with upfront prices

Spravato

Start Your Journey at Hudson Mind

What to Expect

Spravato is an FDA-approved nasal spray for treatment-resistant depression. It works differently from traditional antidepressants by targeting NMDA receptors in the brain, often providing rapid relief. Spravato is administered in a controlled setting under medical supervision to ensure safety and effectiveness.

30%

of people with depression do not respond to antidepressants.

64%

of patients with treatment-resistant depression reported a significant reduction in depressive symptoms after taking Spravato for 3 months.